Received May 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | Z27PB | — |
17-year-old patient received an adult dose of Havrix; 17-year-old patient received an adult dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 17-year-old female patient who received HAV (Havrix) (batch number Z27PB, expiry date 27-AUG-2026) for prophylaxis. On 02-MAR-2025, the patient received the 1st dose of Havrix. On 02-MAR-2025, an unknown time after receiving Havrix, the patient experienced adult product administered to child (Verbatim: 17-year-old patient received an adult dose of Havrix) and overdose (Verbatim: 17-year-old patient received an adult dose of Havrix). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-APR-2025 Other HCP reported that on 02nd May 2025, a 17-year-old patient received an adult dose of Havrix, which led to Adult product administered to child and overdose. It was the first dose of the series.